Chengdu Olymvax Biopharmaceuticals, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Chengdu Olymvax Biopharmaceuticals, Inc.

Why is Chengdu Olymvax Biopharmaceuticals, Inc. ?

With a growth in Operating Profit of 296.87%, the company declared Very Positive results in Mar 25

The company has declared positive results for the last 2 consecutive quarters
OPERATING CASH FLOW(Y) Highest at CNY 33.06 MM
NET PROFIT(HY) At CNY 9.66 MM has Grown at 124.94%
NET SALES(HY) At CNY 287.7 MM has Grown at 35.08%

Market Beating Performance

The stock has generated a return of 130.15% in the last 1 year, much higher than market (China Shanghai Composite) returns of 14.61%

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Chengdu Olymvax Biopharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Chengdu Olymvax Biopharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Chengdu Olymvax Biopharmaceuticals, Inc.

-100.0%

2.53

60.70%

China Shanghai Composite

15.44%

1.01

14.52%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

18.20%

EBIT Growth (5y)

-1.90%

EBIT to Interest (avg)

15.30

Debt to EBITDA (avg)

0.61

Net Debt to Equity (avg)

0.18

Sales to Capital Employed (avg)

0.46

Tax Ratio

15.47%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.29%

ROE (avg)

4.40%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

127

Industry P/E

Price to Book Value

8.21

EV to EBIT

120.29

EV to EBITDA

75.29

EV to Capital Employed

6.99

EV to Sales

11.73

PEG Ratio

0.55

Dividend Yield

ROCE (Latest)

5.81%

ROE (Latest)

6.45%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

24What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 33.06 MM

NET PROFIT(HY)

At CNY 9.66 MM has Grown at 124.94%

NET SALES(HY)

At CNY 287.7 MM has Grown at 35.08%

ROCE(HY)

Highest at 4.37%

RAW MATERIAL COST(Y)

Fallen by -8.78% (YoY

PRE-TAX PROFIT(Q)

At CNY -7.04 MM has Grown at 74.2%

-10What is not working for the Company

INTEREST(9M)

At CNY 11.63 MM has Grown at 63.56%

DEBT-EQUITY RATIO (HY)

Highest at 18.01 %

Here's what is working for Chengdu Olymvax Biopharmaceuticals, Inc.

Operating Cash Flow

Highest at CNY 33.06 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

At CNY 86.98 MM has Grown at 23.55%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

At CNY -7.04 MM has Grown at 74.2%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -7.07 MM has Grown at 72.79%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Raw Material Cost

Fallen by -8.78% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Chengdu Olymvax Biopharmaceuticals, Inc.

Interest

At CNY 7.62 MM has Grown at 40.41%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at 18.01 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio